Oxford Nanopore Technologies posted preliminary H1 2025 revenues of approximately £105 million, up 25% from the same period last year and exceeding company expectations. Growth was driven by both research and applied markets including biopharma, clinical, and industrial segments. Regions EMEAI and Asia Pacific led with over 30% constant currency revenue growth. The PromethIon platform saw revenue growth of approximately 59% year over year. Oxford Nanopore continues to reduce adjusted EBITDA losses through cost management and gross profit growth, targeting full-year revenue growth guidance of 20–23%.